Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Consolidated Net Income (2016 - 2026)

Ironwood Pharmaceuticals' Consolidated Net Income history spans 16 years, with the latest figure at $129.7 million for Q4 2025.

  • On a quarterly basis, Consolidated Net Income rose 178.68% to $129.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $156.0 million, a 193.9% increase, with the full-year FY2025 number at $155.9 million, up 193.84% from a year prior.
  • Consolidated Net Income hit $129.7 million in Q4 2025 for Ironwood Pharmaceuticals, up from $40.1 million in the prior quarter.
  • Over the last five years, Consolidated Net Income for IRWD hit a ceiling of $391.3 million in Q2 2021 and a floor of -$1.1 billion in Q2 2023.
  • Historically, Consolidated Net Income has averaged -$21.3 million across 5 years, with a median of $37.9 million in 2022.
  • Biggest five-year swings in Consolidated Net Income: crashed 3038.3% in 2023 and later skyrocketed 2846.74% in 2025.
  • Tracing IRWD's Consolidated Net Income over 5 years: stood at $41.3 million in 2021, then soared by 177.29% to $114.6 million in 2022, then tumbled by 235.83% to -$155.7 million in 2023, then fell by 5.84% to -$164.8 million in 2024, then soared by 178.68% to $129.7 million in 2025.
  • Business Quant data shows Consolidated Net Income for IRWD at $129.7 million in Q4 2025, $40.1 million in Q3 2025, and $23.6 million in Q2 2025.